Can a virtual support program ease the burden of chronic GVHD?
NCT ID NCT06910969
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a group-based telehealth program called HORIZONS for adults living with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. The program includes 8 sessions led by a therapist to help with self-management and quality of life. Researchers will compare it to just receiving a booklet, aiming to see if the group program makes a real difference.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HORIZONS multidisciplinary group-based telehealth intervention
- What this could lead to
- If it works, this could provide a proven way to help people with chronic GVHD feel better and manage their condition more effectively.
- What could go wrong
- This is a behavioral intervention, not a drug, so it may not work for everyone. The trial is still recruiting, and results are not yet known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE MARROW TRANSPLANT COMPLICATIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
-
University of Miami Sylvester Comprehensive Cancer Center
RECRUITINGMiami, Florida, 33136, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can meditation tame the Long-Term side effects of a stem cell transplant?
- Hidden heart risks in testicular cancer survivors: a closer look at chemotherapy's long shadow
- Could a liquid form of a Graft-Versus-Host disease drug be as effective as the pill?
- Can a cancer drug tame graft-versus-host disease when steroids fail?
- Scientists map immune battlefield in chronic GVHD tissue
- New antibody may offer safer shield against transplant complications